Search results | liver cancer

Reports

Liver Cancer Partnering

The Liver Cancer Partnering provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies

Cancer Vaccine Partnering Agreements

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Cancer vaccine

A cancer vaccine is a vaccine that treats existing cancer or prevents the development…

Drug delivery

Drug delivery is the method or process of administering a drug to achieve a therapeutic effect

4SC seeks three potential pharma partners for cancer drug

4SC AG (VSC) said it’s in talks with at least three potential pharma partners after patients in a mid-stage clinical trial of its liver cancer drug Resminostat combined with Bayer AG (BAYN)’s Nexavar survived for eight months.

Avila Therapeutics and Sanofi-aventis collaborate on cancer treatments

Avila Therapeutics has signed a worldwide strategic alliance with sanofi-aventis. The collaborative R&D and licensing deal will aim to discover covalent drugs for the treatment of cancers.

SciClone Pharmaceuticals: Your marketing partner for China

Sciclone Pharmaceuticals is a specialty pharmaceutical company focused on developing and marketing products to treat oncology, infectious diseases and urology.

China implements stringent pharma licensing laws

In a step that is likely to unnerve global drugmakers, China has overhauled parts of its intellectual property law and mandated compulsory pharma licensing to allow its domestic pharmaceutical industry to make low-cost versions of medicines under patent protection

Bayer predicts 60 percent rise in Asian sales by 2015

Written and published by Reuters.

Chugai Pharmaceutical Ltd – Japan’s number one biopharmaceutical company

Chugai Pharmaceutical manufactures, sells, imports and exports pharmaceuticals and has become the leading biopharmaceutical company in Japan.

Current Agreements Deal Analysis Update : December 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in November 2014 and give you an exclusive opportunity to gain discounted annual subscription access to our database.

Nektar Therapeutics – Well respected partner of choice

Nektar Therapeutics is a leading biopharma company developing clinical stage products based upon its advanced polymer conjugate chemistry technology.

Events

Sorry, your search returned no results.


Deals

Pfizer and Samsung Medical Medical Center collaborate on liver cancer

Samsung Medical Center and Pfizer Inc. announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer.

Merck and Syndax partner for cancer combo clinical

Syndax and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining entinostat, an investigational epigenetic therapy, with KEYTRUDA

Merck Serono and Intrexon in CAR-T cancer pact

Intrexon and Merck Serono announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies

Eli Lilly and Innovent in pact for three cancer treatments

Eli Lilly and Innovent Biologics announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company

BMS and Rigel ink cancer immunotherapies pact

Rigel Pharmaceuticals and Bristol-Myers Squibb have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies

Teva enters into pharma licensing deal with Eagle Pharmaceuticals for cancer drug

Teva Pharmaceutical Industries has entered into a $120 million pharma licensing agreement that will allow it to distribute and promote a competitor to its own cancer drug, Eagle Pharmaceuticals EP-3102.

Boehringer Ingelheim and Vanderbilt partner for RAS inhibitors for cancer

Boehringer Ingelheim has established a research alliance with Vanderbilt University and the cancer drug discovery laboratory

AstraZeneca partners with Molplex for mechanisms of cancer progression

Molplex Pharmaceuticals has announced a pioneering new research collaboration agreement with AstraZeneca

Roche and Foundation Medicine in personalized meds for cancer pact

Foundation Medicine and Roche enter into a broad strategic collaboration to further advance Foundation Medicine’s market-leading position in molecular information and genomic analysis

Collaboration agreement for DEP dendrimer drug delivery technology

Starpharma has signed a second, expanded agreement with AstraZeneca in the field of cancer medicine using Starpharma’s proprietary DEP dendrimer drug delivery technology.